 |
|
The National Cancer Data Base Report on Cancer of the Head and Neck
Henry T. Hoffman, MD;
Lucy Hynds Karnell, PhD;
Gerry F. Funk, MD;
Robert A. Robinson, MD;
Herman R. Menck, MBA
Arch Otolaryngol Head Neck Surg. 1998;124:951-962.
Background The National Cancer Data Base (NCDB), a large sample of cancer cases accrued from hospital-based cancer registries, is sponsored by the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB permits a detailed analysis of case-mix, treatment, and outcome variables.
Objective To provide an overview of the contemporary status of the subset of patients with head and neck cancer in the United States.
Methods The NCDB, which obtains data from US as well as Canadian and Puerto Rican hospitals, accrued 4583455 cases of cancer between 1985 and 1994. Of these cases, 301350 (6.6%) originated in the head and neck. We address 295022 cases of head and neck cancer limited to the 50 United States and District of Columbia. Cases were segregated into an earlier group (1985-1989) to permit 5-year follow-up and into a later group (1990-1994) to analyze a more contemporary group. Comparison between both periods permits identification of trends.
Results The largest proportion of cases arose in the larynx (20.9%) and oral cavity, including lip (17.6%) and thyroid gland (15.8%). Squamous cell carcinoma (55.8%) was the most common histological finding, followed by adenocarcinoma (19.4%) and lymphoma (15.1%). Income level (low), race (African American), and tumor grade (poorly differentiated) were most notably associated with advanced stage. Treatment was most commonly surgery alone (32.4%), combined surgery with irradiation (25.0%), and irradiation alone (18.9%). Overall 5-year, disease-specific survival was 64.0%. Cancer of the lip demonstrated the best survival (91.1%) and cancer of the hypopharynx the worst survival (31.4%).
Conclusions This NCDB analysis of cancer of the head and neck provides a contemporary overview of head and neck cancer in the United States. It also serves to introduce a series of NCDB articles that address specific anatomical sites and histological types through separate, detailed analysis.
From the Departments of Otolaryngology–Head and Neck Surgery (Drs Hoffman, Karnell, and Funk) and Pathology (Dr Robinson), University of Iowa Hospitals and Clinics, Iowa City; and National Cancer Data Base, Commission on Cancer of the American College of Surgeons, Chicago, Ill (Mr Menck).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer
Tai et al.
Jpn J Clin Oncol 2008;0:hyn073v1-7.
ABSTRACT
| FULL TEXT
CT Findings after Laryngectomy
Ferreiro-Arguelles et al.
RadioGraphics 2008;28:869-882.
ABSTRACT
| FULL TEXT
The PDZ Binding Motif of Human Papillomavirus Type 16 E6 Induces PTPN13 Loss, Which Allows Anchorage-Independent Growth and Synergizes with Ras for Invasive Growth
Spanos et al.
J. Virol. 2008;82:2493-2500.
ABSTRACT
| FULL TEXT
The Role of Human Papillomavirus 16 E6 in Anchorage-Independent and Invasive Growth of Mouse Tonsil Epithelium
Hoover et al.
Arch Otolaryngol Head Neck Surg 2007;133:495-502.
ABSTRACT
| FULL TEXT
Depressive Symptoms, Smoking, Drinking, and Quality of Life Among Head and Neck Cancer Patients
Duffy et al.
Psychosomatics 2007;48:142-148.
ABSTRACT
| FULL TEXT
Intensification regimen for advanced-stage resectable hypopharyngeal carcinoma.
Ozer et al.
Arch Otolaryngol Head Neck Surg 2006;132:385-389.
ABSTRACT
| FULL TEXT
Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer.
Kong et al.
Cancer Res. 2006;66:2834-2843.
ABSTRACT
| FULL TEXT
Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness
Celetti et al.
Clin. Cancer Res. 2005;11:8019-8027.
ABSTRACT
| FULL TEXT
Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome
Meissner et al.
Clin. Cancer Res. 2005;11:2552-2560.
ABSTRACT
| FULL TEXT
Therapeutic Decision Making in Stages III and IV Head and Neck Squamous Cell Carcinoma
Gleich et al.
Arch Otolaryngol Head Neck Surg 2003;129:26-35.
ABSTRACT
| FULL TEXT
Human Papillomavirus Type 16 and Squamous Cell Carcinoma of the Head and Neck
Ringstrom et al.
Clin. Cancer Res. 2002;8:3187-3192.
ABSTRACT
| FULL TEXT
The Role of Intratumoral Therapy With Cisplatin/Epinephrine Injectable Gel in the Management of Advanced Squamous Cell Carcinoma of the Head and Neck
Wenig et al.
Arch Otolaryngol Head Neck Surg 2002;128:880-885.
ABSTRACT
| FULL TEXT
Dr Martin: How Are We Doing in 2000?: Hayes Martin Lecture
Byers
Arch Otolaryngol Head Neck Surg 2001;127:759-765.
FULL TEXT
High-Dose Intra-arterial Cisplatin Therapy Followed by Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck
Wilson et al.
Arch Otolaryngol Head Neck Surg 2001;127:809-812.
ABSTRACT
| FULL TEXT
Treatment of Stage III and Stage IV Supraglottic Carcinoma: Should Elderly Patients Undergo Standard Treatment Protocols?
Knudsen
Arch Otolaryngol Head Neck Surg 1999;125:1406-1407.
FULL TEXT
|
